Planned website maintenance is taking place on Tuesday 5 May 2026, from 6.00 pm to 6.30 pm (AEDT). Some pages may be temporarily unavailable. If issues continue outside this time, please contact us.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topics
- Shortages and supply disruptions (22)
- Safety monitoring and information (11)
- Manufacturing (7)
- Compliance and enforcement (6)
- Labelling and packaging (4)
- Import and export (3)
- Scheduling (national classification system) (3)
- Committees and advisory bodies (2)
- Legislation (2)
- Advertising (1)
- Clinical trials (1)
- Fees and payments (1)
- Medicinal cannabis hub (1)
Collection content
113 result(s) found, displaying 1 to 10
-
PageInformation for applicants on requesting and preparing for pre-submission meetings for medicines and biologicals.
-
Medicine shortage alertsSerious Scarcity Substitution Instrument (SSSI) allows continuous access to Catapres (clonidine) 150 mcg tablets during an anticipated new shortage.
-
PageInformation and updates about the shortages of cyclophosphamide and ifosfamide injection.
-
Medicine shortage alertsInformation about the cyclophosphamide and ifosfamide injection shortages.
-
Medicine shortage alertsThe overall supply of methylphenidate modified-release products continues to improve and stabilise.
-
GuidanceGuidance on the mandatory requirements for reporting current and anticipated reportable medicine shortages and discontinuations in Australia.
-
PageOVERALL SUPPLY IS STABLE. THE SSSI LAPSED ON 31 MARCH 2026.
-
PagePharmaceutical companies Novo Nordisk and Eli Lilly are gradually discontinuing some of their earlier generation insulin products. Our webpage lists affected products and includes alternative options.
-
FormsForms for notifying the TGA of a change in sponsorship.
-
PageInformation about the shortage and the Serious Scarcity Substitution Instrument